Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells

Clinical Cancer Research

Volumn 8, Issue 9, 2002, Pages 2976-2984

  Yu, Chunrong ^a   Krystal, Geoffrey ^a   Dent, Paul ^a   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CASPASE; CASPASE 3; CASPASE 8; CELL CYCLE PROTEIN; FLAVOPIRIDOL; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; STAT5 PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

APOPTOSIS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FLAVONOIDS; FUSION PROTEINS, BCR-ABL; HL-60 CELLS; HUMANS; JURKAT CELLS; K562 CELLS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MITOCHONDRIA; PHOSPHORYLATION; PIPERAZINES; PIPERIDINES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIMIDINES; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; U937 CELLS;

EID: 0036715327     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph+) acute lymphocytic leukemia
2. Nonmyristoylated Abl proteins transform a factor-dependent hematopoietic cell line
3. 2-M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
4. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis
5. A requirement for NF-κB activation in Bcr-Abl-mediated transformation
6. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: Protection is correlated with up-regulation of Bcl-xL
7. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway
8. The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells
9. Bcr/Abl activates transcription of the Bcl-X gene through STAT5
10. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL. TEL-ABL, and TEL-PDGFR fusion proteins
11. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148
12. ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis
13. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
14. Roots of clinical resistance to STI-571 cancer therapy
15. Mechanisms of action of flavopiridol
16. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
17. 1 arrest with inhibition of cyclindependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
18. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts
19. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells
20. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
21. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells
22. Characterization of a K562 multidrug-resistant cell line
23. Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-β-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis
24. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway
25. Structural and biochemical basis of apoptotic activation by Smac/DIABLO
26. Pharmacologic mitogen-activated protein kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells
27. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells
28. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents
29. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs
30. Co-treatment with As203 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells
31. Geldanamycin and its analog 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human blasts
32. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia
33. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication
34. 2-M
35. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms
36. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
37. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts
38. Rate-limiting effects of cyclin dl in transformation by ErbB2 predicts synergy between herceptin and flavopiridol
39. Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release
40. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway
41. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells
42. Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells
43. Mechanisms of resistance to the tyrosine kinase inhibitor STI571 and prospects for circumvention by combination with conventional chemotherapeutic agents
44. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
45. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
46. Role of α1 acid glycoprotein in the in vivo resistance of human BCRABL(+) leukemic cells to the abl inhibitor STI571
47. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance